| SPECIALTY-PHARMACIES |
SPECIALTY-PHARMACIES |
90%
|
Two U.S. customers (namely specialty pharmacies) accounted for $290.9 million, or 77%, of our revenues for the year ended December 31, 2025, and $227.7 million, or 77%, of our revenues for the year e… |
| ALMAC-GROUP |
ALMAC-GROUP |
85%
|
ly remained uninterrupted across all commercial markets. C) Joenja® manufacturing Pursuant to our agreement with Novartis relating to Joenja®, we have agreed to manufacture both the drug substance as… |
| MRK |
Merck & Co., Inc. |
72%
|
. Anurag Relan has been an integral part of Pharming for nearly two decades and was appointed Chief Medical Officer in June 2021. He leads the Pharming’s global medical strategy, including clinical d… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from PHAR graph: . Anurag Relan has been an integral part of Pharming for nearly two decades and was appointed Chief Medical Officer in… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from PHAR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from PHAR graph: Reciprocal relationship from SNYN… |
| SNYNF |
Sanofi |
72%
|
roducts could be impacted. We depend on third-party manufacturers for the production of Joenja® and for the production of rhC1INH for commercial supply and for use in clinical trials of RUCONEST®, as… |
| ZLDPF |
Zealand Pharma A/S |
72%
|
. Anurag Relan has been an integral part of Pharming for nearly two decades and was appointed Chief Medical Officer in June 2021. He leads the Pharming’s global medical strategy, including clinical d… |
| ZLDPF |
Zealand Pharma A/S |
72%
|
Reciprocal relationship from ZLDPF graph: Reciprocal relationship from PHAR graph: . Anurag Relan has been an integral part of Pharming for nearly two decades and was appointed Chief Medical Officer … |
| ACM-BIOSCIENCES-AG |
ACM-BIOSCIENCES-AG |
62%
|
. Anurag Relan has been an integral part of Pharming for nearly two decades and was appointed Chief Medical Officer in June 2021. He leads the Pharming’s global medical strategy, including clinical d… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
2024 and 2023 91 Revenues Revenues increased by $51.9 million, or 21.1%, from $245.3 million for the year ended December 31, 2023 to $297.2 million for the year ended December 31, 2024. The increase … |
| COORDINATION-GROUP |
COORDINATION-GROUP |
62%
|
ting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties statute, which im… |
| C-ORGANIZATIONAL-STRUCTURE-PHARMING-GROUP |
C-ORGANIZATIONAL-STRUCTURE-PHARMING-GROUP |
62%
|
ting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties statute, which im… |
| CORPORATE-INFORMATION-PHARMING-GROUP |
CORPORATE-INFORMATION-PHARMING-GROUP |
62%
|
ese financial statements. F-4 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME For the year ended December 31, Amounts in $ ‘000 Notes 2025 2024 2023 Profit (loss) for the year 2,538 ( 11,841 ) ( 10,54… |
| EXPERT-GROUP |
EXPERT-GROUP |
62%
|
ly remained uninterrupted across all commercial markets. C) Joenja® manufacturing Pursuant to our agreement with Novartis relating to Joenja®, we have agreed to manufacture both the drug substance as… |
| F-14-BIOLOGICAL-ASSETS-THE-GROUP |
F-14-BIOLOGICAL-ASSETS-THE-GROUP |
62%
|
ents. The resulting accounting estimates will, by definition, seldom equal the related actual results. The main estimates and assumptions that have a risk of causing an adjustment to the carrying amo… |
| ISOMERASE-THERAPEUTICS-LIMITED |
ISOMERASE-THERAPEUTICS-LIMITED |
62%
|
ents. The resulting accounting estimates will, by definition, seldom equal the related actual results. The main estimates and assumptions that have a risk of causing an adjustment to the carrying amo… |
| KYOWA-KIRIN-CO-LTD |
KYOWA-KIRIN-CO-LTD |
62%
|
mv, a European investment company listed on Euronext Brussels. The existing shareholders (including Pharming) reached agreement with Gimv on the sale of all issued and outstanding shares to a new hol… |
| LEASES-THE-GROUP |
LEASES-THE-GROUP |
62%
|
sfied at a point in time (typically for promises to transfer goods to a customer) or over time (typically for promises to transfer services to a customer). For a performance obligation satisfied over… |
| MEMBER-STATE-COORDINATION-GROUP |
MEMBER-STATE-COORDINATION-GROUP |
62%
|
ting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties statute, which im… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
endors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations. Misc… |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
endors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations. Misc… |
| PHARMING-AUSTRALIA-PTY-LTD |
PHARMING-AUSTRALIA-PTY-LTD |
62%
|
ases. An entity is considered effectively controlled if the Company, directly or indirectly, has the power to govern the financial and operating policies of an entity so as to obtain benefits from it… |
| PHARMING-GROUP |
PHARMING-GROUP |
62%
|
rket were $ 311.7 million and $ 246.6 million, respectively. In 2023, the sales of RUCONEST® in the U.S. market were $ 221.2 million. Revenues of RUCONEST® in Europe and Rest of the World amounted to… |
| PHARMING-HEALTHCARE-INC |
PHARMING-HEALTHCARE-INC |
62%
|
ases. An entity is considered effectively controlled if the Company, directly or indirectly, has the power to govern the financial and operating policies of an entity so as to obtain benefits from it… |
| PHARMING-ORPHANPACIFIC-INC |
PHARMING-ORPHANPACIFIC-INC |
62%
|
ly remained uninterrupted across all commercial markets. C) Joenja® manufacturing Pursuant to our agreement with Novartis relating to Joenja®, we have agreed to manufacture both the drug substance as… |
| PHARMING-UK-LTD |
PHARMING-UK-LTD |
62%
|
ases. An entity is considered effectively controlled if the Company, directly or indirectly, has the power to govern the financial and operating policies of an entity so as to obtain benefits from it… |
| YUNGJIN-PHARM-CO-LTD |
YUNGJIN-PHARM-CO-LTD |
62%
|
ly remained uninterrupted across all commercial markets. C) Joenja® manufacturing Pursuant to our agreement with Novartis relating to Joenja®, we have agreed to manufacture both the drug substance as… |
